

## Title

Virologic characterization of symptom rebound following nirmatrelvir-ritonavir treatment for COVID-19

## Authors

Julie Boucau, Ph.D.<sup>1</sup>  
Rockib Uddin, B.S.<sup>2</sup>  
Caitlin Marino, B.S.<sup>1</sup>  
James Regan, B.S.<sup>3</sup>  
James P. Flynn, B.S.<sup>3</sup>  
Manish C. Choudhary, Ph.D.<sup>3,4</sup>  
Geoffrey Chen, B.A.<sup>2</sup>  
Ashley M. Stuckwisch, B.S.<sup>2</sup>  
Josh Mathews, A.B.<sup>2</sup>  
May Y. Liew, B.A.<sup>2</sup>  
Arshdeep Singh, B.S.<sup>2</sup>  
Zahra Reynolds, M.P.H.<sup>2</sup>  
Surabhi L. Iyer, B.A.<sup>2</sup>  
Grace C. Chamberlin, B.A.<sup>2</sup>  
Tammy D. Vyas, B.S.<sup>2</sup>  
Jatin M. Vyas, M.D., Ph.D.<sup>2,4</sup>  
Sarah E. Turbett, M.D.<sup>2</sup>  
Jonathan Z. Li, M.D.<sup>3,4\*</sup>  
Jacob E. Lemieux, M.D., D. Phil.<sup>2,4,5\*</sup>  
Amy K. Barczak, M.D.<sup>1,2,4\*</sup>  
Mark J. Siedner, M.D., M.P.H.<sup>2,4\*+</sup>

## Affiliations:

1. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2. Massachusetts General Hospital, Boston, MA, USA
3. Brigham and Women's Hospital Boston, MA, USA
4. Harvard Medical School, Boston, MA, USA
5. Broad Institute, Cambridge, MA, USA

\* contributed equally

+ Communicating author:

Mark Siedner, MD MPH  
100 Cambridge Street, Suite 1600  
Medical Practice Evaluation Center  
Massachusetts General Hospital  
Boston, MA 02114  
617-726-4686  
[msiedner@mgh.harvard.edu](mailto:msiedner@mgh.harvard.edu)

## **Abstract**

We enrolled seven individuals with recurrent symptoms following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log<sub>10</sub> copies/mL) were detected at enrollment and for a median of 17 days after initial diagnosis. Three of seven had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

## 1 **Background**

2 Nirmatrelvir-ritonavir, which inhibits the main viral protease of SARS-CoV-2, has been shown to  
3 reduce hospitalization in high-risk patients with early stage, symptomatic COVID-19 infection [1].  
4 The US Food and Drug Administration granted emergency use authorization (EUA) status for its  
5 use in December, 2021 and it is currently a preferred therapy for ambulatory individuals with  
6 COVID-19 at high risk of severe disease [2]. As nirmatrelvir-ritonavir has entered into broad  
7 clinical use, reports have emerged of recurrent symptoms in a subset of treated individuals who  
8 had initial symptomatic improvement [3]. However, the mechanism and viral characteristics of  
9 symptomatic relapse after nirmatrelvir-ritonavir therapy remain unclear. We sought to  
10 characterize the virology of symptomatic rebound after nirmatrelvir-ritonavir with longitudinal  
11 sampling of individuals with assessment of nasal swabs with viral load quantification, viral  
12 culture, and whole genome viral sequencing.

13

## 14 **Methods**

### 15 *Study participants*

16 The POSITIVES cohort is a longitudinal study of individuals with COVID-19 infection that aims  
17 to characterize virologic and immunologic aspects of infection [4–6]. To better understand the  
18 clinical phenomenon of symptom relapse after nirmatrelvir-ritonavir treatment, we selectively  
19 enrolled seven ambulatory individuals recently treated with nirmatrelvir-ritonavir with recurrent  
20 symptoms after initial resolution. Individuals were identified through the Mass General Brigham  
21 health system or upon referral from treating providers and contacted by phone for informed  
22 consent at the time of symptom recurrence. Following enrollment, anterior nasal (AN) swabs  
23 were collected and placed into viral transport media three days per week until PCR negativity.  
24 Swabs were simultaneously analyzed for viral RNA level by qRT-PCR, viral whole genome  
25 sequencing, semiquantitative viral culture, and laboratory-based rapid antigen testing.

26

27 *Viral load quantification*

28 Viral transport media was centrifuged for 2 hours at 21,000 x g and 4°C to pellet virions. TRIzol-  
29 LS™ Reagent (ThermoFisher) was then added to the pellets, and samples were subsequently  
30 incubated on ice for 10 minutes. Chloroform (MilliporeSigma) was added to each sample, and  
31 the resulting mixtures were then vortexed and centrifuged for 15 minutes at 21,000 x g and 4°C.  
32 The clear aqueous layer was collected and concentrated using isopropanol precipitation. RNA  
33 was washed with cold 70% ethanol before being resuspended in DEPC-treated water  
34 (ThermoFisher). SARS-CoV-2 viral RNA was tested with a qPCR assay using the US CDC  
35 2019 nCoV\_N1 primer and probe set and quantified using a standard curve.

36

37 *SARS-CoV-2 culture*

38 Viral culture was performed in the BSL3 laboratory of the Ragon Institute of MGH, MIT, and  
39 Harvard. Viral culture was assessed semi-quantitatively by median tissue culture infectious dose  
40 assay (TCID50) as previously reported [4,6]. Briefly, aliquoted viral transport media were filtered  
41 with 0.45-0.65µm centrifugal filters and added to Vero-E6 cells plated in DMEM culture media  
42 supplemented with 2% fetal bovine serum, HEPES, antibiotic-antimycotic solution and 5µg/mL  
43 of polybrene. Each sample was added to the cells in four replicates and serially diluted six times  
44 in 5-fold increments in 96-well format. The infection was performed by spinfection for one hour  
45 at 2,000x g at 37°C. The cytopathic effect (CPE) was scored seven days post-infection with light  
46 microscopy and TCID50/mL titers were calculated using the Reed-Muench method. The  
47 supernatant of wells showing CPE was harvested for RNA extraction and viral sequence  
48 confirmation.

49

50 *SARS-CoV-2 Whole Genome Sequencing*

51 We sequenced SARS-CoV-2 genomes using the Illumina COVIDSeq Test protocol as  
52 previously described [4]. We constructed sequencing libraries using the Illumina Nextera XT  
53 Library Prep Kit and sequenced them using an Illumina NextSeq 2000 instrument. Complete  
54 genomes (>24,000 assembled base pair length) were assigned a Pango lineage using pangolin  
55 v4.0.6. All samples were deposited to GenBank (Bioproject Accession PRJNA759255) and  
56 GISAID. Notable amino acid mutations and sequence quality were analyzed using Nextclade  
57 v1.14.1.

58

#### 59 *Antigen testing using Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay*

60 Frozen viral transport media aliquots were thawed on ice and 50 $\mu$ L was transferred to a test  
61 tube. Swabs from BinaxNow antigen kits (Abbott, Chicago, IL) were immersed into the liquid  
62 until fully absorbed and then tested according to manufacturer's instructions as previously  
63 described [7]. After 15 minutes, result were interpreted as positive, negative, or discordant by a  
64 reader blinded to the viral load result.

65

#### 66 *Ethical considerations*

67 Study procedures were approved by the human subject's review committee at Mass General  
68 Brigham and all participants gave informed consent to participate.

69

## 70 **Results**

71 Participant demographic details are provided in Supplemental Table 1. All seven participants  
72 reported symptom improvement and conversion to negative home-based antigen testing  
73 following treatment with nirmatrelvir-ritonavir. Symptoms recurred a median of 9 days after initial  
74 positive test or 4 days after completion of the nirmatrelvir-ritonavir course. At study enrollment,  
75 all seven participants had a detectable viral load (median 6.1 log<sub>10</sub> copies per mL [range 4.2-

76 7.3]). A detectable viral load was identified for a median of 17 days (range 14-20) after their  
77 initial PCR test and for 12 days (range 9-16) after initiation of nirmatrelvir-ritonavir (**Fig. 1**).  
78 Enrollment sample viral cultures were positive in three of seven individuals. In these three  
79 individuals, cultures were positive up until 10,16, and 16 days, respectively from the time of their  
80 initial PCR test and 5, 11, and 11 days after completion of the course of nirmatrelvir-ritonavir.

81

82 We sequenced virus in six of the seven participants after completion of therapy. We found no  
83 known resistance-associated mutations in nsp5 encoding the main SARS-CoV-2 protease  
84 (Supplemental Figure 1) or in any of the protease cleavage sites.

85

86 Finally, using laboratory-based antigen testing, we found high concordance between antigen  
87 and viral culture testing (92%, 24/26). Although there were two specimens that were antigen  
88 positive and culture negative, no specimens were antigen negative and culture positive.

89

## 90 **Discussion**

91 Symptomatic relapse after nirmatrelvir-ritonavir therapy for early stage COVID-19 infection is  
92 associated with high viral load and, in a subset of individuals, culturable virus. We identified live  
93 virus at up to 11 days after completion of nirmatrelvir-ritonavir therapy (16 days from the pre-  
94 treatment PCR test). By contrast, we recently reported that untreated outpatients infected with  
95 the Omicron variant SARS-CoV-2 shed viable virus for a median of 5 days after an initial  
96 positive test [6]. These data reinforce the importance of testing and isolation guidelines for  
97 individuals with recurrent symptoms after nirmatrelvir-ritonavir treatment, irrespective of  
98 intermediate negative antigen testing or initial symptom resolution. Because live viral shedding  
99 can occur at the time of relapse, restarting monitoring and isolation from the time of relapse may  
100 be warranted.

101 Although field-based testing is needed to confirm our findings, we found high concordance  
102 between laboratory-based rapid antigen testing and culture positivity, with no specimens that  
103 were antigen negative and culture positive. Consequently, antigen test-based monitoring of  
104 individuals with relapse after therapy holds promise as a means of signaling a safe release from  
105 isolation.

106  
107 Finally, we did not identify emergence of any resistance-associated polymorphisms in any of the  
108 six specimens that were sequenced. Our findings add support to others that drug resistance  
109 does not appear to be a significant contributor to relapse [3,8] and suggest that nirmatrelvir-  
110 ritonavir may retain activity in most cases of symptom recrudescence.

111  
112 Our study should be interpreted in the context of limitations. Most notably, this represents a  
113 small case series so precise estimates of culture positivity, duration of viral shedding, or  
114 incidence of drug resistance cannot be made. We also enrolled individuals after clinical  
115 rebound, so cannot determine the incidence of this syndrome among individuals taking  
116 nirmatrelvir-ritonavir treatment. Finally, we use viral culture as a proxy measure of  
117 contagiousness but cannot quantify the risk of transmission for this patient population.

118  
119 In summary, recurrent clinical disease after nirmatrelvir-ritonavir therapy for COVID-19 is  
120 associated with high viral load and, in some cases, culturable virus. Culturable virus was  
121 present for up to two weeks after completion of therapy. Consideration should be given to  
122 revising public health guidelines to specifically recommend repeat testing and isolation in these  
123 cases. Future work is needed to better understand the causes, clinical significance, and public  
124 health consequences of symptomatic relapse after nirmatrelvir-ritonavir.

125  
126

## **Acknowledgements**


The authors would like to thank Vamsi Thiriveedhi, Ha Eun Cho, and Seamus Carroll for assistance with sequencing. We would also like to thank the participants for their time and participation, as well as the many physicians for referral of patients to our study.

## **Funding**

This study was supported by the Massachusetts Consortium for Pathogen Readiness (grants to Drs. Li, Lemieux, Siedner, and Barczak) and the Massachusetts General Hospital Department of Medicine (grant to Dr. Vyas). The BSL3 laboratory where viral culture work was performed is supported by the Harvard CFAR (P30 AI060354).

## References

1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *N Engl J Med* **2022**; 386:1397–1408.
2. Therapeutic Management of Nonhospitalized Adults With COVID-19. Available at: <https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/>. Accessed 20 May 2022.
3. Charness M, Gupta K, Stack G, et al. Rapid Relapse of Symptomatic Omicron SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/Ritonavir. 2022. Available at: <https://www.researchsquare.com>. Accessed 20 May 2022.
4. Siedner MJ, Boucau J, Gilbert RF, et al. Duration of viral shedding and culture positivity with post-vaccination SARS-CoV-2 delta variant infections. *JCI Insight* **2021**; :e155483.
5. Seaman MS, Siedner MJ, Boucau J, et al. Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses. *medRxiv* **2022**; :2022.03.02.22271731.
6. Boucau J, Marino C, Regan J, et al. Duration of viable virus shedding in SARS-CoV-2 omicron variant infection. *medRxiv* **2022**; :2022.03.01.22271582.
7. Regan J, Flynn JP, Choudhary MC, et al. Detection of the Omicron Variant Virus With the Abbott BinaxNow SARS-CoV-2 Rapid Antigen Assay. *Open Forum Infect Dis* **2022**; 9:ofac022.
8. FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID. Available at: <https://www.fda.gov/media/155050/download>. Accessed 20 May 2022.



**Figure 1.** Virologic and clinical course of individuals with symptomatic recurrence of COVID-19 following nirmatrelvir-ritonavir treatment.

WGS: whole genome sequencing, N/R: nirmatrelvir-ritonavir